Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Prior treatment

• Was administered a live vaccine ≤ 4 weeks before treatment;
• Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment;
• Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection;
• Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;

Other illness

• Active leptomeningeal disease or uncontrolled, untreated brain metastasis;
• Active autoimmune diseases or history of autoimmune diseases that may relapse;
• With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases;

Lab values

• Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody;

• Age≥18 years old, male or female, signed Informed Consent Form (ICF);
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• Histologically or cytologically confirmed ES-SCLC;
• No prior systemic treatment for ES-SCLC;
• At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation;
• Adequate hematologic and end organ function;